1- Consensus on How to Conduct Follow-Up in Peripheral Vascular Disease

Peripheral vascular disease involves multiple areas and, therefore, can have very different presentations (from complete lack of symptoms to disabling symptoms). Depending on clinical presentation, general condition, anatomical localization, and lesion extension, revascularization can be indicated alongside optimal medical treatment.

Read also HERE

2- Percutaneous Annuloplasty in Functional Mitral Regurgitation vs. Sham Procedure

In cases where it is difficult to demonstrate the improvement of a drug or a device in hard endpoints such as mortality, we should look for softer and easier to prove endpoints. The problem is that these soft endpoints are often subjective (such as sensation of shortness of breath or angina pectoris) and they could be biased by a drug or device placebo effect. 

Read also HERE

3- Secondary Prevention: A Responsibility We Should Not Delegate

After coronary angioplasty, the use of drugs whose efficacy for the reduction of major events has been proven declines over time, which is associated with worse patient prognosis.

Read also HERE

4- Off-hours Primary PCI Still Have the Highest Mortality Rate?

According to this contemporary study, in the current organized STEMI network, patients admitted to a tertiary high-volume center for primary PCI are managed similarly and have similar prognosis regardless admission time. 

Read also HERE

5- What is Optimal Blood Pressure?

In the last 30 years, the clinical practice guidelines on both sides of the Atlantic have been lowering blood pressure thresholds. From the starting 160 mmHg systolic blood pressure to 130 mmHg or even 120 mmHg. 

Read also HERE

6- Unilateral Vascular Access in TAVR: Our Main Procedure, Increasingly Minimalist

There has been a significant decline in vascular complications in the last few years due to improvements in device profiles and operator experience on transcatheter aortic valve replacement (TAVR).

Read also HERE

7- Benefit of Anticoagulation in the Elderly with Atrial Fibrillation

Guidelines recommend oral anticoagulation for all ≥ 75-year-old patients with atrial fibrillation. However, there is little evidence as to its net clinical benefit in the elderly population.

Read also HERE

8- The Most Read Articles of November at Solaci.org

See the most read scientific articles of November on solaci.org.

Read also HERE

9- Mechanisms of Infarction in Coronary Arteries with Non-Significant Lesions

Infarctions with non-obstructive coronary artery disease, also known as MINOCA (myocardial infarction with nonobstructive coronary arteries), often present plaque rupture and thrombi associated with the affected myocardial territory. In these patients, optical coherence tomography (OCT) is of great value to identify the “culprit”.

Read also HERE

10- Net Benefit of Left Atrial Appendage Closure vs. Anticoagulation in Atrial Fibrillation

This analysis shows that the long-term clinical benefit of left atrial appendage closure with Watchman is superior to warfarin in patients with atrial fibrillation (AF). The initial peri-procedural risks of device implantation are counterbalanced over time, with reduced risk of bleeding and death. 

Read also HERE

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.